DexCom (NASDAQ:DXCM) Posts Earnings Results, Misses Estimates By $0.05 EPS

DexCom (NASDAQ:DXCM) issued its quarterly earnings data on Thursday. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05), Zacks reports. DexCom had a net margin of 17.22% and a return on equity of 31.40%.

DexCom Stock Performance

DXCM stock traded up $0.22 during trading on Thursday, hitting $84.09. 6,781,111 shares of the company traded hands, compared to its average volume of 3,443,240. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market cap of $32.85 billion, a PE ratio of 50.35, a P/E/G ratio of 2.26 and a beta of 1.14. The stock’s 50-day simple moving average is $82.11 and its 200 day simple moving average is $75.19. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DXCM. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Leerink Partners cut their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, Raymond James lowered their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $98.41.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,342 shares of company stock worth $3,628,069. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.